Merck receives FDA approval for Bravecto monthly chew for fleas and ticks

Merck Animal Health announced that the FDA has approved Bravecto 1-Month chews for dogs and puppies eight weeks of age and older. Bravecto works to treat and prevent fleas and to treat and control ticks.

Bravecto is suitable for dogs in the early stages of life, before transitioning to extended duration Bravecto products when the dog reaches six months of age, according to Merck.

“The approval of this additional Bravecto product builds on the strong foundation and body of scientific evidence that we have established over the years with our broad-spectrum, comprehensive line of parasite protection products,” said KJ Varma, senior vice president of research and development at Merck.

Bravecto 1-Month contains fluralaner, an ectoparasiticide that has shown systemic activity against ticks and fleas, according to Merck.

The product is available in five strengths: 45, 100, 200, 400 and 560 milligrams per chew. The monthly chew is expected to be available in the coming months.